Please ensure Javascript is enabled for purposes of website accessibility

Better Marijuana Stock to Buy: Cresco Labs or Trulieve?

By David Jagielski – May 19, 2020 at 7:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Which is the safer investment to make today?

Cresco Labs (CRLBF -9.30%) and Trulieve Cannabis (TCNNF -6.38%) are two of the biggest and most well-known cannabis companies in the U.S. However, their share prices have been faring very differently in 2020, with Trulieve down a modest 5% while Cresco's stock has crashed by 45% -- well below even the Horizons Marijuana Life Sciences ETF (HMLSF -8.37%), which has declined 33%. Let's take a closer look at whether Trulieve is still likely to outperform over the remainder of the year, or whether Cresco's larger loss makes it the more likely stock to achieve better gains from here on out.

Has Cresco Labs become too risky a stock to own?

Chicago-based Cresco Labs released its audited annual results on April 28, and the numbers weren't pretty. Although revenue of $128.5 million over the past year was triple the $43.3 million that the vertically integrated cannabis company generated in the previous year, Cresco actually ended up posting a significant net loss of $65.3 million in 2019, compared with a $3.1 million profit in 2018. Rising operating expenses and a smaller boost from changes in fair value were behind the results.  Its net loss of $45.2 million in the fourth quarter was the largest the company has incurred since its founding in 2013.

Cannabis edibles.

Image source: Getty Images.

And with cannabis companies facing some serious challenges ahead, given that consumers might end up tightening their wallets during COVID-19, things may not get better for Cresco in future quarters. There are already signs that the company's outlook may not be as rosy as it was before.

For example, on April 27, Cresco announced it was backing out of a $282.5 million deal to purchase Tryke, a cannabis operator with locations in Nevada and Arizona. Cresco CEO Charlie Bachtell blamed the canceled transaction on a number of factors -- regulatory challenges, declining valuations in the industry, and COVID-19. The company is aware of the risks ahead and is adjusting its plans, and investors may want to do the same. Cresco could be in for a rough ride this year.

Trulieve continues pumping out profits -- but are they sustainable?

On April 8, Florida-based Trulieve released its annual results for 2019. Unlike Cresco, Trulieve's had no problem posting a profit, having done so in each of the past six quarters. But those figures don't come without an asterisk. In 2019, its net income of $178 million would've looked a lot different had Trulieve not benefited from fair value adjustments on inventory sold and growth of biological assets, which added nearly $200 million to the company's gross margin. In the previous year, when Trulieve recorded a profit of $27.9 million, fair value adjustments totaled $36.9 million.

The danger here for investors is that those fair value adjustments add a lot of noise to the company's financials and can make future earnings reports unpredictable, because they'll have a significant effect on the company's bottom line. Without significant (and positive) adjustments, Trulieve could easily land in the red. After backing out those items, the cannabis company's results don't look nearly as impressive. But one area where Trulieve sets itself apart from Cresco is in market share.

While Trulieve's sales came short of tripling in 2019, at $252.8 million in revenue for the year, the company generated nearly twice the sales that Cresco did during the past year. And what's impressive is that Florida's responsible for much of Trulieve's success, as 47 of its 49 locations are in the Sunshine State, where medical marijuana is legal but recreational use is not. The company announced on May 5 that its latest dispensary would be its fourth to open in the Orlando area. Outside of Florida, Trulieve also has operations in Connecticut, California, and Massachusetts. By comparison, Cresco Labs operates in nine states.

Why Trulieve's still the better buy today

Simplicity is important for the cannabis industry these days. Companies are scaling back growth and walking away from deals in an effort to cut down costs and keep their operations lean. Trulieve is heavily invested in a hot Florida market that's allowed the company to become one of the top pot stocks in the country without much expansion into other states, proving that a large national footprint isn't necessary to do well. And while COVID-19 may affect demand for cannabis, medical marijuana is less likely to see volatility than the recreational market, since it's more of a necessity. That means Trulieve may do well despite the pandemic. With more sales and a simpler operation, Trulieve is the safer stock to invest in today, and it's likely to continue outperforming Cresco Labs this year.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Cresco Labs Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trulieve Cannabis Stock Quote
Trulieve Cannabis
$9.24 (-6.38%) $0.63
Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
$2.73 (-9.30%) $0.28
Horizons Marijuana Life Sciences Index ETF Stock Quote
Horizons Marijuana Life Sciences Index ETF
$4.49 (-8.37%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.